The U.S. Food and Drug Administration (FDA) has approved the use of the ProHance MRI contrast agent by Bracco Diagnostics for use in MRI scans of pediatric patients.
ProHance (gadoteridol) is a gadolinium-based contrast agent now indicated for intravenous use with MRI in patients less than 2 years old, including full-term newborns. The agent, which was previously approved for patients older than 2, visualizes areas with disrupted blood brain barriers and/or abnormal vascularity throughout the brain, spine, and associated tissues.
